{
  "abstract": "BACKGROUND: Immune checkpoint inhibitor (ICI)-related inflammatory arthritis occurs in approximately 6% of ICI-treated patients, and is often long-lasting. The clinical presentation is heterogeneous, and often loosely resembles either rheumatoid arthritis (ICI-IA) with peripheral presentation, or polymyalgia rheumatica (ICI-PMR) with predominant bilateral shoulder and hip pain and stiffness. Our objective was to compare clinical features, immunosuppressive treatment, and cancer outcomes between ICI-IA and ICI-PMR. METHODS: Data were extracted from the Rheumatology Adverse Events Due to Immunotherapy Observational Study multicenter prospective registry, regarding patients with rheumatologist-diagnosed ICI-IA or ICI-PMR and no preexisting primary IA/PMR. Clinical features were collected at the first visit in the registry. Multivariable logistic regression was used to compare second-line immunosuppressive drug utilization between groups. Kaplan-Meier curves were constructed to compare time of prednisone tapering to a dose of (1) 10 mg and (2) 5 mg from the baseline registry visit. Cox proportional hazard models were used to compare progression-free survival (PFS). Date of first cancer progression from arthritis onset was extracted based on documentation of imaging and/or pathology in the medical record. Patients with ICI-PMR were also compared with an independent cohort of patients with primary PMR. RESULTS: We analyzed 490 patients: 418 with ICI-IA and 72 with ICI-PMR. Compared with patients with ICI-IA, patients with ICI-PMR were older (70 vs 63 years old, p<0.001), more likely to be male (p=0.034), had shorter onset after ICI initiation (87 vs 125 days, p=0.011) and had less peripheral synovitis (15% vs 72%, p<0.001). Time to a prednisone dose of 10 and 5 mg/day was comparable between groups. Patients with ICI-IA were more likely to receive a second-line immunosuppressive drug (OR 3.51 (95% CI 1.50 to 8.21, p=0.004)). PFS was comparable between groups. Compared with primary PMR (n=189), the sex ratio was inversed in ICI-PMR, but there was a similar proportion with peripheral arthritis (15%). CONCLUSIONS: Patients with ICI-IA were more likely to require a second-line immunosuppressive drug than patients with ICI-PMR, but PFS was the same. Future therapeutic clinical trials in ICI-IA/PMR should stratify patients according to phenotype.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "name": "Alice Tison"
    },
    {
      "name": "Deanna Jannat-Khah"
    },
    {
      "name": "Laura Cappelli"
    },
    {
      "name": "Maria Suarez-Almazor"
    },
    {
      "name": "Noha Abdel-Wahab"
    },
    {
      "name": "Pankti Reid"
    },
    {
      "name": "Jeffrey Sparks"
    },
    {
      "name": "Tawnie Braaten"
    },
    {
      "name": "Alexa Meara"
    },
    {
      "name": "Cassandra Calabrese"
    },
    {
      "name": "Tamiko Katsumoto"
    },
    {
      "name": "Nilasha Ghosh"
    },
    {
      "name": "Kyle Ge"
    },
    {
      "name": "Alain Saraux"
    },
    {
      "name": "Valérie Devauchelle-Pensec"
    },
    {
      "name": "Ami Shah"
    },
    {
      "name": "Clifton Bingham"
    },
    {
      "name": "Anne Bass"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e99gdpnt08npp.bib",
  "cited_by": 2,
  "doi": "10.1136/jitc-2025-014641",
  "fulltext_url": null,
  "id": "e99gdpnt08npp",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://hal.science/hal-05837572v1",
  "language": "en",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.imm"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7162632226",
  "pdf_url": null,
  "pmcid": null,
  "pmid": "42208976",
  "published": "2026-05-28",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/e99gdpnt08npp.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:01Z",
      "native_id": "hal-05837572",
      "source": "hal",
      "url": "https://hal.science/hal-05837572v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.imm",
      "subfield": "immunology"
    }
  ],
  "title": "Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study",
  "title_text": "Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:01Z",
  "url": "https://research.draconitic.com/paper/e99gdpnt08npp",
  "venue": "Journal for Immunotherapy of Cancer",
  "versions": []
}